Obseva SA (NASDAQ:OBSV) – Analysts at Wedbush decreased their FY2021 earnings per share estimates for shares of Obseva in a research report issued on Wednesday, November 28th. Wedbush analyst L. Moussatos now expects that the company will earn ($2.90) per share for the year, down from their previous forecast of ($2.84). Wedbush has a “Buy” rating and a $34.00 price objective on the stock. Wedbush also issued estimates for Obseva’s FY2022 earnings at ($2.08) EPS.
A number of other brokerages have also recently commented on OBSV. Zacks Investment Research upgraded shares of Obseva from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research report on Thursday, October 18th. HC Wainwright set a $44.00 target price on shares of Obseva and gave the company a “buy” rating in a research report on Monday, October 15th. TheStreet upgraded shares of Obseva from a “d+” rating to a “c-” rating in a research report on Thursday, October 11th. JPMorgan Chase & Co. initiated coverage on shares of Obseva in a research report on Thursday, September 13th. They issued an “overweight” rating and a $29.00 target price for the company. Finally, Leerink Swann initiated coverage on shares of Obseva in a report on Wednesday, August 15th. They issued an “outperform” rating and a $25.00 price objective for the company. Eight analysts have rated the stock with a buy rating, Obseva has a consensus rating of “Buy” and an average target price of $29.43.
Shares of NASDAQ OBSV opened at $13.99 on Monday. The stock has a market capitalization of $509.74 million, a PE ratio of -6.22 and a beta of 1.75. Obseva has a 52 week low of $9.05 and a 52 week high of $20.35.
Obseva (NASDAQ:OBSV) last issued its earnings results on Thursday, November 8th. The company reported ($0.42) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.04.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. VHCP Management III LLC purchased a new stake in shares of Obseva in the third quarter valued at about $20,911,000. Renaissance Technologies LLC grew its holdings in shares of Obseva by 191.8% in the third quarter. Renaissance Technologies LLC now owns 100,100 shares of the company’s stock valued at $1,805,000 after purchasing an additional 65,800 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Obseva in the third quarter valued at about $728,000. Vivo Capital LLC grew its holdings in shares of Obseva by 1.3% in the third quarter. Vivo Capital LLC now owns 937,147 shares of the company’s stock valued at $16,897,000 after purchasing an additional 12,147 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in shares of Obseva in the third quarter valued at about $720,000. 70.58% of the stock is owned by hedge funds and other institutional investors.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Recommended Story: What is an SEC Filing?
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.